Johnson K, Aplenc R, Bagatell R. Survival by race among children with extracranial solid tumors in the United States 1985-2005 [abstract]. American Society for Clinical Oncology (ASCO); 2010 Jun; Chicago, IL.
Fox E, Aplenc R, Widemann BC, Chuk MK, Bagatell R, Kim A, et al. Phase I trial and pharmacokinetic study of cediranib in children with recurrent or refractory solid tumors. AACR/EORT Molecular Targets Meeting; 2009 Nov; Boston, MA.
Bagatell R, Herzog CE, Trippett TM, Winter E, Dall GC, Grippo JF, et al. Pharmacokinetically guided phase I trial of the IGF-1 antagonist RG1507 administered weekly. AACR/EORTC Molecular Targets Meeting; 2009 Nov; Boston, MA.
Bagatell R, Wagner LM, Cohn SL, Maris JM, Reynolds CP, Stewart CF, et al. Irinotecan + temozolomide in children with recurrent or refractory neuroblastoma: a phase II Children's Oncology Group study, American Society for Clinical Oncology (ASCO); 2009 Jun; Orlando, FL.
2012, Richard and Sheila Sanford Endowed Chair in Pediatric Oncology
2006-present, Best Doctors in America
2006, Alpha Omega Alpha
2002, Vernon and Virginia Furrow Award for Excellence in Clinical Science Teaching for Medical Students
2001, University Animal Care Outstanding Investigator Award, University of Arizona
2000, Children's Oncology Group Young Investigator Award
2000, University of Arizona, College of Medicine, Dean's Physician Scientist Career Development Award
1999, Pharmacia-Upjohn Outstanding Fellow Award, Arizona Cancer Center
1996, Resident of the Year, Pima County Pediatric Society
1996, Resident Teacher of the Year Award, Department of Pediatrics, University of Arizona
1993, Hugh Thompson Award, Outstanding Medical Student in Pediatrics
1989-93, Dean's Scholar, University of Arizona
1987, Phi Beta Kappa
Parikh S, Bagatell R. Bone tumors. In: Florin TA, Ludwig S, editors. Netter's pediatrics. Philadelphia: Saunders Elsevier; 2011. Ch. 60, p. 366-71.
Bagatell R, Park J. Neuroblastoma. In: Lanzkowsky P, editor. Handbook of pediatric hematology and oncology. 5th ed. London, UK: Academic Press; 2011. Ch. 22, p. 671.
Adamson P, Bagatell R, Balis FM, Blaney SM. In: Pizzo PA, Adamson PC, Poplack DG (eds). Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins. 2010.
Editorial Board, The Oncologist
Ad Hoc Reviewer:
The Children's Hospital of Philadelphia:
American Association for Cancer Research
American Society for Clinical Oncology
American Society of Pediatric Hematology/Oncology
American Academic of Pediatrics
2010-present, Alex's Lemonade Stand Foundation Grant Review Committee
2009-present, Developmental Therapeutics Steering Committee
2009-present, Children's Oncology Group
2008-present, High Risk Neuroblastoma Induction Task Force, Co-chair
2008-present, ANBL0812 Phase II Trial, Study Vice Chair
2008-2009, American Society of Clinical Oncology Grant Selection Executive Committee
2007-2009, American Society of Clinical Oncology Grant Selection Committee
2007-present, Children's Neuroblastoma Cancer Foundation Medical Advisory Board
2007-present, Neuroblastoma Steering Committee
2006-2009, Neuroblastoma Biology Committee
Advances in Neuroblastoma Research, Advisory Board
Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, et al. Pharmacokinetically guided phase I trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res. 2011 Feb 1;17(3):611-9. Epub 2010 Dec 2. Cited in PubMed: PMID 21127194. Read the abstract
Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 10;29(2):208-13. Epub 2010 Nov 29. Cited in PubMed: PMID 21115869. Read the abstract
Johnson KA, Aplenc R, Bagatell R. Survival by race among children with extracranial solid tumors in the United States between 1985 and 2005. Pediatr Blood Cancer. 2011 Mar;56(3):425-31. Cited in PubMed: PMID 21072824. Read the abstract
Trippett TM, Herzog C, Whitlock JA, Wolff J, Juttesch J, Bagatell R, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigator's consortium. J Clin Oncol. 2009 Oct 20:27(30):5102-8. Epub 2009 Sep 21. Cited in PubMed: PMID 19770383. Read the abstract
Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2009 Jan 20;27(3):365-70. Epub 2008 Dec 1. Cited in PubMed: PMID 19047282. Read the article
Bagatell R. Clinical trials and experimental therapies [invited lecture]. Childhood Cancer Symposium, Alex's Lemonade Stand Foundation; 2010 Jun 26; Philadelphia, PA.
Bagatell R. New endpoint and trial design to define the dose of a molecularly targeted anti-cancer agent in children [invited lecture]. Children's Cancer Research Center Seminar, The Children's Hospital of Philadelphia; 2009 Sep 8; Philadelphia, PA.
Bagatell R. How to read the medical literature [invited lecture]. Children's Neuroblastoma Cancer Foundation Conference; 2009 Jul 18; Chicago, IL.« Back to Previous Page